Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ion Niculescu-Duvaz

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Opinion in Molecular Therapeutics|June 4, 2010
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancerIon Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|November 15, 2002
Glufosfamide (Baxter Oncology)Ion Niculescu-Duvaz
Current Opinion in Molecular Therapeutics|November 13, 2004
Technology evaluation: EMD-273063, EMD LexigenIon Niculescu-Duvaz
Methods in Molecular Medicine|December 6, 2003
Introduction to the background, principles, and state of the art in suicide gene therapyIon Niculescu-Duvaz, Caroline J Springer
Molecular Biotechnology|April 5, 2005
Introduction to the background, principles, and state of the art in suicide gene therapyIon Niculescu-Duvaz, Caroline J Springer
Methods in Molecular Medicine|December 6, 2003
Design of prodrugs for suicide gene therapyDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Caroline J Springer
Trends in Molecular Medicine|April 3, 2002
The emerging fields of suicide gene therapy and virotherapyDavid Kirn, Ion Niculescu-Duvaz, Gunnel Hallden, et al.
Current Medicinal Chemistry|July 23, 2003
Gene regulation in cancer gene therapy strategiesIan Scanlon, Panos Lehouritis, Ion Niculescu-Duvaz, et al.
Expert Opinion on Therapeutic Patents|January 9, 2013
BRAF as a therapeutic target: a patent review (2006 - 2012)Alfonso Zambon, Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, et al.
Bioorganic & Medicinal Chemistry Letters|January 7, 2012
Small molecule inhibitors of BRAF in clinical trialsAlfonso Zambon, Ion Niculescu-Duvaz, Dan Niculescu-Duvaz, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Opinion in Molecular Therapeutics|June 4, 2010
Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancerIon Niculescu-Duvaz
Current Opinion in Investigational Drugs (London, England : 2000)|November 15, 2002
Glufosfamide (Baxter Oncology)Ion Niculescu-Duvaz
Current Opinion in Molecular Therapeutics|November 13, 2004
Technology evaluation: EMD-273063, EMD LexigenIon Niculescu-Duvaz
Methods in Molecular Medicine|December 6, 2003
Introduction to the background, principles, and state of the art in suicide gene therapyIon Niculescu-Duvaz, Caroline J Springer
Molecular Biotechnology|April 5, 2005
Introduction to the background, principles, and state of the art in suicide gene therapyIon Niculescu-Duvaz, Caroline J Springer
Methods in Molecular Medicine|December 6, 2003
Design of prodrugs for suicide gene therapyDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Caroline J Springer
Trends in Molecular Medicine|April 3, 2002
The emerging fields of suicide gene therapy and virotherapyDavid Kirn, Ion Niculescu-Duvaz, Gunnel Hallden, et al.
Current Medicinal Chemistry|July 23, 2003
Gene regulation in cancer gene therapy strategiesIan Scanlon, Panos Lehouritis, Ion Niculescu-Duvaz, et al.
Expert Opinion on Therapeutic Patents|January 9, 2013
BRAF as a therapeutic target: a patent review (2006 - 2012)Alfonso Zambon, Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, et al.
Bioorganic & Medicinal Chemistry Letters|January 7, 2012
Small molecule inhibitors of BRAF in clinical trialsAlfonso Zambon, Ion Niculescu-Duvaz, Dan Niculescu-Duvaz, et al.
Pageof 3